כל הפוסטים במחקרים ופרסומים

Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study

28/02/2024 9:21

Buisson A et.al.; Aliment Pharmacol Ther. 2024 Feb;59(4):526-534

קרא עוד ←

Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease

06/11/2023 12:49

Roblin X et.al.; J Crohns Colitis. 2023 Nov 2:jjad188

קרא עוד ←

Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease

13/08/2023 9:24

Smith PJ et.al.; Expert Rev Clin Immunol. 2023 Jul-Dec;19(9):1143-1156.

קרא עוד ←

Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial

07/08/2023 9:28

Constantin A et.al.; Rheumatology (Oxford). 2023 Aug 1;62(8):2838-2844

קרא עוד ←

Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial

01/04/2023 15:04

D’Haens et.al.; Clinical Drug Investigation 2023 Apr;43(4):277-288

קרא עוד ←

Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study

08/09/2022 14:58

Smith et.al.; Journal of Crohn's and Colitis, 2022 Sep 8;16(9):1436-1446

קרא עוד ←

Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study

17/08/2022 14:54

Buisson et.al.; Clinical Gastroenterology and Hepatology 2023 Aug;21(9):2338-2346

קרא עוד ←

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

28/06/2022 15:11

Peyrin‑Biroulet et.al.; BMC Gastroenterology 2022 Jun 8;22(1):291

קרא עוד ←

Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: A case series

20/01/2022 12:53

Baraliakos X et.al.; Clin Case Rep. 2022 Jan 20;10(1):e05205.

קרא עוד ←

Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: A case series

10/01/2022 16:14

Vijayan S et.al.; Clin Case Rep. 2022 Jan 13;10(1):e05233

קרא עוד ←

1
2